Sunday, September 20, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchsemaglutidetirzepatideketoacidosisfaerspharmacovigilance

Cureus study compares ketoacidosis reports for semaglutide and tirzepatide

The disproportionality analysis draws on FDA Adverse Event Reporting System data for non-diabetic patients using the two incretin drugs for obesity.

PR
By Priya Raman · Science Reporter
May 14 03:00 ETSource: Cureus

The wire

  1. 01A Cureus disproportionality analysis examined ketoacidosis signals in FAERS among non-diabetic patients taking semaglutide or tirzepatide for obesity.
  2. 02Clinicians prescribing incretins off the diabetes label may want a euglycemic ketoacidosis differential for patients presenting with malaise, nausea or dyspnea.
  3. 03FAERS is a spontaneous reporting system, so disproportionality signals cannot establish incidence or causation and are subject to reporting bias.

From the source

Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Read at cureus.com
Source URL https://www.cureus.com/articles/487988-ketoacidosis-risk-in-non-diabetic-patients-using-semaglutide-versus-tirzepatide-for-obesity-a-disproportionality-analysis-of-the-fda-adverse-event-reporting-system